Abstract Number: 1060 • ACR Convergence 2022
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
Background/Purpose: This study aimed to characterise the main clinical features of patients with systemic sclerosis (SSc) sine scleroderma (ssSSc) in comparison with the limited cutaneous…Abstract Number: 1520 • ACR Convergence 2022
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in systemic sclerosis (SSc). Emerging evidence suggests a beneficial effect of tocilizumab…Abstract Number: 1874 • ACR Convergence 2022
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease…Abstract Number: 0035 • ACR Convergence 2022
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…Abstract Number: 0508 • ACR Convergence 2022
Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…Abstract Number: 1062 • ACR Convergence 2022
Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in systemic sclerosis (SSc). The diagnosis and monitoring of ILD is based on…Abstract Number: 1524 • ACR Convergence 2022
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…Abstract Number: 1959 • ACR Convergence 2022
Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of RA. Studies have shown variability in the prevalence and mortality rate of patients with…Abstract Number: 0048 • ACR Convergence 2022
Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice
Background/Purpose: Respiratory-related diseases are among the most common causes of death in rheumatoid arthritis (RA). Although autoimmune diseases are reported in higher frequency in females,…Abstract Number: 0520 • ACR Convergence 2022
Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III
Background/Purpose: Scleroderma Lung Study (SLS) II established mycophenolate mofetil (MMF) as an active therapy for scleroderma-related interstitial lung disease (SSc-ILD) and the need to consider…Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…Abstract Number: 1526 • ACR Convergence 2022
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…Abstract Number: 0050 • ACR Convergence 2022
Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid…Abstract Number: 0521 • ACR Convergence 2022
Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Background/Purpose: Black patients with systemic sclerosis (SSc) develop SSc at a younger age and have more severe disease than White patients, including a higher prevalence…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 39
- Next Page »